Enhancing erythropoietin therapy in ischaemia-reperfusion injury of heart and kidney

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/631576

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $361,021.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cardiology (incl. Cardiovascular Diseases)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Apoptosis | Cardiac failure | Cardiovascular diseases | Cardiovascular pharmacology | Ischaemia-reperfusion | Ischaemic acute renal failure | Myocardial infarction | Oxidative stress | Pathophysiology | Renal failure

Related Links